Introducing MedGeneRx® HP 30 PRP
PRP Kit Specifications 30cc Protocol
• FDA Cleared, Class II Medical Device, 510(k)
• Integrated anticoagulant- No ACD-A needed
• Industry leader in three critical areas:
– Reproducible concentrations from consistent platelet recovery/85+%
– Balanced pH
– 99% removal of RBCs
• Vacutainer system for simplified blood collection
• Compatible with existing 30mm diameter centrifuges
• Single spin 30 cc’s of whole blood
– 5 cc’s high concentration PRP
– 15 cc’s mid concentration PRP
Platelet Kit Description
MedGeneRx® HP 30 PRP Kit is FDA Cleared and indicated for the rapid preparation of autologous Platelet Rich Plasma (PRP) from a small sample of blood at the patient’s point -of-care.
SKU: ZG-PRP-HP30
MedGeneRx® HP 30 PRP Kit Components
(1) MedGeneRx® HP 30 Vacutainer
(2) 10cc Syringes
(1) 21g Butterfly Needle
(1) 3 inch 19g Spinal Needle
Performance Data
510(k) equivalence study conducted and the following mean results were achieved:
• Platelet Concentration Factor at 0 hours = 3.8-4.1x baseline
• Platelet Concentration Factor at 1 Hour = 4.1-4.3 x baseline
• Platelet Recovery % at 1 hours = 53%
• RBC at 0 hours- 0.1
• RBC at 4 hours- 0.01
• pH at 0 hours = 7.59
• pH at 4 Hours = 7.69
• Platelet Activation resting at 0 hours= 9.7%
• Platelet Activation stimulated ADP 0 hours = 95.1%
• Platelet Aggregation at 0 hours = 95.1%
• Platelet Aggregation at 4 Hours = 94.8%
• HCT at 0 hours = 0.0 %
• HCT at 4 Hours = 0.0%
• WBC at 0 hours= 0.3
• WBC at 4 hours= 0.3
PRP Articles
Platelet-rich plasma versus hyaluronic acid in the treatment of knee osteoarthritis: a meta-analysis
Abstract Background This study aimed to evaluate the clinical efficacy of platelet-rich plasma (PRP) injection compared with hyaluronic acid (HA) injection for patients undergoing knee
Increasing Platelet Concentration in Platelet-Rich Plasma Inhibits Anterior Cruciate Ligament Cell Function in Three-Dimensional Culture
Abstract The anterior cruciate ligament (ACL) is a key stabiliz-er of the knee that is prone to injury, especially inyoung, active women. The annual incidence
Treatment of Tendon and Muscle Using Platelet-Rich Plasma
Abstract Musculoskeletal injuries and impairments result in over 100 million office visits in the United States per year. Tendons and muscle-related issues account for a
Treatment of Chronic Wounds with Autologous Platelet-Rich-Plasma
Abstract After treatment with platelet-rich plasma, 50% of the wounds had healed, 35.7% had reduced in size and 14.2% were unchanged in terms of area
Treatment of Chronic Elbow Tendinosis With Buffered Platelet-Rich Plasma
Abstract Treatment of patients with chronic elbow tendinosis with buffered platelet-rich plasma reduced pain significantly in this pilot investigation. Further evaluation of this novel treatment
Prevention of Disc Degeneration with Growth Factors
Abstract Clinically, a large number of patients have persistent low back pain attributable to intervertebral disc (IVD) degeneration. After the concept of biologically regenerating the
Platelet-Rich plasma- New clinical application- A pilot study for treatment of jumper’s knee
Abstract This study describes a simple, low-cost, minimally invasive way to apply PRP growth factors to chronic patellar tendinosis; 20 male athletes with a mean
Platelet-Rich Plasma- From Basic Science to Clinical Applications
Abstract Research into the biology of bone, ligament, and tendon healing has led to the development of a variety of products designed to help stimulate
Platelet Rich Plasma Injection Grafts for Musculoskeletal Injuries- A Review
Abstract In Europe and the United States, there is an increasing prevalence of the use of autologous blood products to facilitate healing in a variety
Platelet Rich Plasma in Rotator Cuff Repair
Abstract Despite clinical success rates over 85%, persistent anatomic defects after rotator cuff repair are common and depend on the size of the tear repaired.
We’re here to help your patients and your practice.
Through innovative technology, preparation & training.
